Cooper Companies Q1 Revenue Climbs 6.2% to $1.02 Billion as Profit Jumps 25%

The Cooper Companies, Inc. (NYSE: COO), a global medical device manufacturer specializing in contact lenses and women's healthcare products, reported revenue of $1.02 billion for the three months ended January 31, 2026, a 6.2% increase from $964.7 million in the same period a year earlier. Net income climbed 25.4% to $130.8 million compared to $104.3 million in the prior-year quarter. Read more earnings reports.

Operating income reached $212.8 million, up 16.9% from $182.0 million a year ago. The company's gross profit margin expanded to 67.9% from 68.4% in the year-ago period, as gross profit rose to $695.2 million from $660.2 million.

Segment Performance

The company's CooperVision segment, which manufactures contact lenses, generated $695.1 million in revenue for the quarter, up 7.6% from $646.1 million a year earlier. The CooperSurgical segment, focused on women's healthcare, posted $329.0 million in revenue compared to $318.6 million in the prior-year quarter, a 3.3% increase.

CooperVision operating income reached $210.2 million, up from $183.9 million a year ago. CooperSurgical reported operating income of $26.8 million compared to $20.2 million in the same quarter last year.

Expenses and Profitability

Cost of goods sold rose to $328.9 million from $304.5 million a year earlier. Research and development expenses increased to $44.3 million from $40.7 million, while selling, general and administrative expenses ticked up to $390.2 million from $387.9 million.

Diluted earnings per share came in at $0.66, compared to $0.52 in the prior-year quarter. The weighted average diluted share count declined to 196.7 million from 201.2 million a year ago.

Cash Flow and Balance Sheet

Cash from operations reached $260.9 million for the quarter, up 36.9% from $190.6 million a year earlier. The company used $102.9 million for investing activities and $147.9 million for financing activities.

Total assets stood at $12.42 billion as of January 31, 2026, up slightly from $12.39 billion at the end of the prior fiscal year on October 31, 2025. Cash and cash equivalents increased to $124.9 million from $110.6 million. Long-term debt declined to $1.88 billion from $2.46 billion at the end of the previous quarter.

Total stockholders' equity rose to $8.36 billion from $8.24 billion. The company had 195.1 million common shares outstanding as of January 31, 2026, down from 195.9 million at October 31, 2025.

Working Capital

Accounts receivable declined to $807.1 million from $829.0 million at the end of the prior quarter. Inventory increased to $876.4 million from $846.0 million. Accounts payable decreased to $225.8 million from $300.4 million.